|Bid||78.95 x 100|
|Ask||80.10 x 100|
|Day's Range||76.05 - 79.97|
|52 Week Range||27.64 - 80.00|
|PE Ratio (TTM)||-9.87|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||89.43|
NEW YORK, NY / ACCESSWIRE / May 26, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against Puma Biotechnology, Inc. ("Puma" or the "Company") (NASDAQ: PBYI) ...
Shares of Puma Biotechnology, Inc. (PBYI) have risen 35% since it announced that an FDA advisory committee recommended the approval of its lead pipeline candidate, neratinib for the treatment of some breast cancers.
As of late, it has definitely been a great time to be an investor in Puma Biotechnology Inc (PBYI).